Study Details
Testing the Study Drug Guselkumab to Treat Children with Juvenile Psoriatic Arthritis
(IRB#: IRB_00145602)
Juvenile Psoriatic Arthritis (jPsA) is a condition that causes chronic joint pain and swelling along with red patches on the skin or a silvery-white buildup of dead skin. This study will test guselkumab to treat children with jPsA. The study wants to see if the drug will help people with the condition and is safe. Participants in the study will receive the study drug guselkumab. The drug is taken as a liquid shot under the skin. Being in the study requires attending in-person visits at the study clinic and lasts about 52 weeks. Medical tests will be done during the study to track the health of participants.
- All genders
- Under 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Under 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 5 to 18 years old
- Diagnosis of Juvenile Psoriatic Arthritis (jPsA) by Vancouver inclusion criteria
- Active disease in at least 3 joints before participation (defined as swelling OR loss of motion with pain and/or tenderness)
- Able to attend in-person visits at the study clinic
Exclusion Criteria
- Diagnosis of enthesitis-related arthritis
- History of chronic infection such as a chest infection (bronchiectasis) and infected skin wound
- History of Hepatitis C infection
- History of HIV infection
- Pregnant
Will I be paid for my time?
Yes
IRB#: IRB_00145602
PI: John Bohnsack
Department: PEDIATRICS
Approval Date: 2022-10-19 06:00:00
Specialties: Rheumatology
I am Interested